Drivers of absolute systemic bioavailability after oral pulmonary inhalation in humans - Université d'Angers Accéder directement au contenu
Article Dans Une Revue European Journal of Pharmaceutics and Biopharmaceutics Année : 2021

Drivers of absolute systemic bioavailability after oral pulmonary inhalation in humans

Résumé

There are few studies in humans dealing with the relationship between physico-chemical properties of drugs and their systemic bioavailability after administration via oral inhalation route (Fpulm). Getting further insight in the determinants of Fpulm after oral pulmonary inhalation could be of value for drugs considered for a systemic delivery as a result of poor oral bioavailability, as well as for drugs considered for a local delivery to anticipate their undesirable systemic effects. To better delineate the parameters influencing the systemic delivery after oral pulmonary inhalation in humans, we studied the influence of physico-chemical and permeability properties obtained in silico on the rate and extent of Fpulm in a series of 77 compounds with or without marketing approval for pulmonary delivery, and intended either for local or for systemic delivery. Principal component analysis (PCA) showed mainly that Fpulm was positively correlated with Papp and negatively correlated with %TPSA, without a significant influence of solubility and ionization fraction, and no apparent link with lipophilicity and drug size parameters. As a result of the small sample set, the performance of the different models as predictive of Fpulm were quite average with random forest algorithm displaying the best performance. As a whole, the different models captured between 50 to 60% of the variability with a prediction error of less than 20%. Tmax data suggested a significant positive influence of lipophilicity on absorption rate while charge apparently had no influence. A significant linear relationship between Cmax and dose (R(2) = "0.79) highlighted that Cmax was primarily dependent on dose and absorption rate and could be used to estimate Cmax in humans for new inhaled drugs.
Fichier principal
Vignette du fichier
Bacle et al - 2021- Drivers of absolute systemic bioavailability.pdf (1.04 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03222648 , version 1 (16-06-2021)

Identifiants

Citer

Astrid Bacle, Guillaume Bouzillé, Arnaud Bruyère, Marc Cuggia, Olivier Fardel, et al.. Drivers of absolute systemic bioavailability after oral pulmonary inhalation in humans. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 164, pp.36-53. ⟨10.1016/j.ejpb.2021.04.014⟩. ⟨hal-03222648⟩
67 Consultations
60 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More